| Outcome Measures: |
Primary: Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17, Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17, Baseline through Day 113 | Secondary: Changes in glycosylated hemoglobin (HbA1c) from baseline to week 9, Changes in glycosylated hemoglobin (HbA1c) from baseline to week 9, Baseline through Day57|The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7% at week 9 and 17, The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7% at week 9 and 17, Day57 and 113|Change in fasting plasma glucose (FPG) from baseline to week 9 and 17, Change in fasting plasma glucose (FPG) from baseline to week 9 and 17, Baseline through Day57 and 113|Change in weight from baseline to week 9 and 17, Change in weight from baseline to week 9 and 17, Baseline through Day57 and 113|Mean postprandial blood glucose increment and change in mean postprandial blood glucose from baseline at 7-point Self-monitored Blood Glucose (SMBG) Profile., Mean postprandial blood glucose increment and change in mean postprandial blood glucose from baseline at 7-point Self-monitored Blood Glucose (SMBG) Profile., Baseline through Day113|Change in 7-point Self-monitored Blood Glucose (SMBG) Profile., Change in 7-point Self-monitored Blood Glucose (SMBG) Profile., Baseline through Day113|Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline to week 17., Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline to week 17., Baseline through Day113|Proportion of subjects receiving remedial therapy at week 17, Proportion of subjects receiving remedial therapy at week 17, Day113|Number of TEAEs and SAEs from baseline to week 17, Number of TEAEs and SAEs from baseline to week 17, Day-14 through Day 113|Ctrough will be measured once every 4 week until week 17, Ctrough will be measured once every 4 week until week 17, Day1, 29, 57, 85 and 113|The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab)., The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab)., Day1, 29, 57, 85, 113 and127
|
